Table 1

Demographic details of patients undergoing intravenous to subcutaneous infliximab switch

Number (%)
Total patients75 (100)
Male44 (58.7)
Female31 (41.3)
Crohn’s disease61 (81.3)
Ulcerative colitis14 (18.7)
Median age37